Radioactive seeds zapped tumors from the inside — but trial stopped early
NCT ID NCT03886181
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early study tested a device that places radioactive seeds directly into skin, mouth, or soft tissue tumors. The seeds release alpha radiation to kill cancer cells from within. Only 2 people took part before the trial was stopped, so we don't have enough information to know if it works or is safe.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Diffusing Alpha Radiation Emitters Therapy (DaRT) device
What this could lead to
If it works, this could offer a new way to treat superficial tumors by delivering targeted radiation from inside the tumor.
What could go wrong
This very early trial was terminated after enrolling only 2 people, so we have very little data. The approach may not prove safe or effective in larger studies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SKIN CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
IRCCS Istituto Dermatologico S. Gallicano, IFO - Istituti Fisioterapici Ospitalieri - Dermatologia Oncologica e Prevenzione
Rome, Lazio, Italy